Relmada Therapeutics (RLMD) Shares Outstanding (Diluted Average) (2015 - 2026)

Relmada Therapeutics (RLMD) has 9 years of Shares Outstanding (Diluted Average) data on file, last reported at $86.6 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $86.6 million, up 184.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.6 million (up 184.77% YoY), and the FY2025 annual result was $39.5 million, up 30.88% from the prior year.
• Shares Outstanding (Diluted Average) grew to $86.6 million in Q1 2026 per RLMD's latest filing, from $39.5 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $86.6 million in Q1 2026 and troughed at $28.4 million in Q1 2022.
• A 5-year average of $34.1 million and a median of $30.1 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Diluted Average) advanced 0.11% in 2024, then surged 184.77% in 2026.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $29.6 million in 2022, then increased by 1.59% to $30.1 million in 2023, then climbed by 0.21% to $30.2 million in 2024, then jumped by 30.88% to $39.5 million in 2025, then surged by 119.35% to $86.6 million in 2026.
• Business Quant data shows RLMD's Shares Outstanding (Diluted Average) at $86.6 million in Q1 2026, $39.5 million in Q4 2025, and $32.3 million in Q3 2025.